摘要
2016年美国国家综合癌症网络(NCCN)乳腺癌临床实践指南(第1版)更新涉及诊断与评估,外科手术,新辅助化疗,辅助化、放疗,靶向治疗,内分泌治疗,晚期解救治疗及随访等方面。回顾NCCN乳腺癌临床实践指南引进中国的10年历程,从依据肿瘤TNM分期实施群体治疗,到推荐参考肿瘤病理学免疫组化结果实施分类治疗,标志我国乳腺癌临床诊治逐渐进入规范化、专业化阶段。第二代测序技术联合其他非解剖学信息,建立个体化预后评价系统,是美国癌症联合会(AJCC)和国际抗癌联盟(UICC)联合制定的第8版TNM分期系统的更新亮点。其中,推荐针对包括乳腺癌在内7类肿瘤作为研究方向,对乳腺癌本质的深入认识将推动乳腺癌进入个体化诊治新阶段。
Updates of the National Comprehensive Cancer Network （NCCN） Guidelines for breast cancer involved workup, surgical treatment, preoperative systemic therapy, systemic adjuvant treatment, radiotherapy, targeted therapy, endocrine therapy, treatment of recurrence/stage IV disease and follow-up. Since the NCCN Guidelines were introduced into China ten years ago, diagnosis and treatment of breast cancer have achieved prominent progress from group-based therapy based on TNM stage to classification treatment based on pathology and immanohistoehemistry, symbolizing specialization and standardization of the diagnosis and treatment of breast cancer in China. The next-generation sequencing technology and other non-anatomical information will be used to build an individual prognostic system, which is the highlight of the 8th edition TNM cancer staging system. Seven kinds of tumor including breast cancer have been selected. A deeper understanding of the nature of breast cancer will build a bridge to the Personalized Medicine.
出处
《中国实用外科杂志》
CSCD
北大核心
2016年第10期1066-1072,共7页
Chinese Journal of Practical Surgery
基金
首都医学发展科研基金资助项目(No.2009-1011)
首都临床特色应用研究资助项目(No.Z131107002213007)
